Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. Professional Research on Cannabis Industry, Initial Public Offerings (IPO), and Alternative Investments including Options, Leveraged ETFs, Penny Stocks, and other alternative investments strategies. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations. While reflecting on what geniuses we are for having backed the truck up on some shares of Illumina a few years back, we decided to analyze the company’s competitive position in order to help us sleep well at night. At the low end is a $20,000 desktop sequencer that put sequencing within reach of more scientists. Illumina Advantage large-scale sequencing products offer the highest level of service and support to ensure operational success for clinical laboratories. Illumina bought Solexa, a company that pioneered what’s called sequencing by synthesis, a faster and less expensive method. Illumina, Inc. managers can use Porter Five Forces to understand how the five competitive forces influence profitability and develop a strategy for enhancing Illumina, Inc. competitive advantage and long term profitability in Biotechnology industry. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. “Illumina didn’t lock itself into being just a sequencing company. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. “It gives the company a solid protection in that sense.”. Illumina already held 70 percent of the market for genome-sequencing machines when it made a landmark announcement in January: using 10 of … Returns as of 01/24/2021. The advantage Illumina has in all of these cases, however, is that it has strong insider knowledge of Grail. But it’s unclear whether they aim to go head-to-head with Illumina, target part of Illumina’s business or open up new markets. The growth in this market is majorly driven by technological advancements in sequencing procedures, surge in genome mapping programs, and increase in drug discovery platforms demanding NGS technology. It would also be a defensive move against Oxford Nanopore’s … While San Diego companies have been quiet, the U.K’s Oxford Nanopore Technologies has publicly gunned for Illumina. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Get advice and learn alternative investments strategies. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. The demand from researchers is also diversifying, as each researchers have different projects and they want to use the platform that best suits for their purposes. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. While Illumina is the 800-pound gorilla, Pellini sees room for other players. It would also be a defensive move against Oxford Nanopore’s long-read platform. To mitigate this risk, the company has been investing heavily in research and development, expects to launch new products this year, and has just completed a major acquisition to bolster its competitive advantage: Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Stock Advisor launched in February of 2002. The real risk for Illumina is losing its grip on the market and ceding share to rivals as the market accelerates. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. The main fear is that Illumina as the supplier is in a position to out-compete on price. (Other ex-Illumina employees have started ventures in genomics areas they say Illumina hasn’t touched.). So said Shawn Baker, principal consultant at SanDiegOmics.com, a genomics consulting company. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. They know it and created a very aggressive sales force there. Illumina’s just-approved system is to fit small-sized sequencing tasks, which is a large and flexible market, Zheng said. DNA-testing services like 23andMe. Collaboration uncovers insights that have the power to create competitive advantage. Guardant360 has several different applications. Mordor Intelligence Sep 30, 2016, 01:30 ET. An advantage of the dominance of Illumina is that everybody is compatible which each other, like all the Microsoft Windows / Office users, but this also means like in the Microsoft top days that they can do and ask whatever they want from their customers. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The Illumina retrofit technology takes full advantage of the high performance Fujifilm 300 Series inks. Stiff Competition Between Illumina, Thermo Fisher Scientific and Roche in the Next Generation Sequencing Market News provided by. Breeding livestock for desirable traits. If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. 3 Stocks That Will Make You Richer in 2021, 3 Unstoppable Stocks That Could Double Your Money, The 3 Best Healthcare Stocks to Buy for 2021, Why Guardant Health Tumbled by Over 10% on Monday. Illumina delivers a comprehensive experience, from fundamental sequencing to data insight services. But achieving the $100 genome is only part of the competitive equation, observers said. Be Aware. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. Collaboration uncovers insights that have the power to create competitive advantage. Create A Compelling Vision - Establishes a clear strategic vision and inspires passion for Illumina’s mission by promoting innovation, leveraging industry expertise, and creating a competitive advantage … Friday, January 15 2021 Breaking News. Analyst Dan Leonard said that Illumina’s long-standing competitive advantage and the long-term trends in next-gen sequencing, or NGS, are positives. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. For now at least. This report analyses the Molecular Breeding’s industry coverage, current market competitive status, and market outlook. Insights from competitive research analysis will provide a competitive advantage to industries/clients in the Array Market industry. These technologies range from the tiny iSeq machines to massive NovaSeq ones, and they … Weakness of Illumina – Internal Strategic Factors . Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. To take advantage of the opportunities, the report recommends the next generation sequencing companies to focus on Artificial Intelligence, invest in big data, expand in emerging markets, focus on premium pricing, and focus on increasing awareness of the benefits of NGS. Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Certain companies achieve a level of success, and at various points along the way individuals who were involved early on peel off and they get involved in the next generation of startups,” said Michael Pellini, managing partner of San Diego-based venture fund Section 32. Illumina's gene-sequencing machines expedited the process of decoding DNA and made it more affordable. This lack of choice can give a new competitor a foothold in the … To enable greater efficiency for these labs, Illumina Advantage products feature: Single lot shipments; Kit lot testing; Extended shelf life; Advance change notification; Certificate of analysis Illumina has always been considered a leader in the gene-sequencing market. Winner = Illumina. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Order & download for $12 Like Qualcomm Inc. before it, Illumina has reached a size where longtime employees break off for local startups. Illumina improved on the technology, while generating new patents. To gain a competitive edge, Illumina must upgrade its organization and infrastructure appropriately and develop products with superior throughput, cost and … Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. We do believe that by the end of this year or early next year we will be at a place to discuss,” an Omniome spokeswoman said. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Hospitals searching for genetic clues to life-threatening cases. Reply Like. Ron Ribitzky, a national consultant in precision medicine and health informatics, said Illumina ticks these boxes, a competitive advantage. The case settled the same year. Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. “Unless they’re raising money — and want to talk up the platform and technology to command better terms — there’s generally no advantage to talk about what they’re doing,” Baker said. Its latest platform is meant to rival Novaseq, though industry watchers have questioned whether the accuracy matches Illumina’s. Weakness are the areas where Illumina can improve upon. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a … scorpion.north. More important: data accuracy, reproducibility and helping customers put data into action. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Illumina declined to comment for the article, only pointing to a recent presentation on the $100 genome. It’s unfortunate, he said, because competition would only benefit sequencing. It’s also aggressively shut out competitors. Jan 05, 2018 | Julia Karow. Illumina COLDCURE sets a new standard for flexo printing speed on standard paper and film stock – potentially doubling your print speed compared to traditional UV or waterbase flexo options. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. The silicon-based nanopore approach has other advantages over Illumina's current approach, including one notable consideration for the future of … To gain a competitive edge, Illumina must upgrade its organization and infrastructure appropriately and develop products with superior throughput, cost and … This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. “Across all industries, sometimes a dominant player emerges but with time and technological advancement, we start to see other opportunities in the marketplace. Finally, we have the most important thing to measure: the sustainable competitive advantages -- or the moats-- that protect each company. Affect Change. The company reported net income rose 12 percent year over year during the quarter, reaching $233 million. There are gaps in the product range sold by the company. Illumina - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for … These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Mutation of these genes increased fitness values conveying a phenotypic advantage during root colonization, although less competitive than the wild type. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. iCrowd Newswire - Jul 1, 2020 Next-Generation Sequencing (NGS) Market Research Study – The exploration report comprised with market data derived from primary as well as secondary research techniques.The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is considered to be market forces. Illumina had a gross margin of 66.25% for the quarter that ended in Sep. 2020 => Durable competitive advantage. Illumina had a gross margin of 66.25% for the quarter that ended in Sep. 2020 => Durable competitive advantage. In January 2018, Illumina launched iSeq 100 Sequencing System that delivers accurate data at low cost. Need Help with Illumina Value Chain Analysis? Order & download for $12 Insights from competitive research analysis will provide a competitive advantage to industries/clients in the Immune Repertoire Sequencing Market industry. This system offers reliability and robustness for broad range of applications ranging from somatic tumor and germline profiling to targeted gene expression and 16S microbial analysis. Last year, Omniome landed a $60 million series B round to develop DNA sequencing that claims to be accurate, fast and at a low cost. Illumina Inc, founded in April 1998 is a biotech company that develops, manufactures, and markets integrated systems for the analysis of variation in genes and genomes. So nanoString has significant competitive advantage providing the same/better? When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Dr. David Smith, the chairman of a Mayo Clinic Center technology assessment committee, said Illumina’s dominance appears almost insurmountable. Illumina is committed to establishing collaborative partnerships with qualified small and diverse suppliers and recognizes the importance of ensuring our supply base reflects the diversity of the communities in which we live, work and serve. If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. “An incremental improvement won’t challenge Illumina. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Marketline's Illumina, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Illumina, Inc. since January2007. Alliance Program partners receive a range of resources and support to help their prospective customers. Analyst Puneet Souda said the company does this for a range of industries, giving Illumina scale that wards off competition. Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. Illumina Inc. Thermo Fisher Scientific Inc. Better Coronavirus Stock: Quidel or Guardant Health? But potential competition is stirring, including in Illumina’s backyard. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. Roswell is chasing this goal via DNA technology that integrates molecules into electronic circuits. Companies Mentioned . All these factors contribute to the sustainability of Illumina’s … There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Illumina is now a CPP Alliance Gold Partner CPP’s Alliance Program recognises and supports independent consulting companies that use CPP's market-leading psychometric instruments at the heart of their client service offerings. The nearly $1 million Novaseq 6000 is expected to one day unlock the $100 genome. The report identifies … But the coming expiration of key Solexa patents could, in theory, open the door to competition. Illumina is by far the largest supplier of DNA sequencing systems, both in the UK and worldwide, and the merging businesses are already close competitors. “It’s no different than Boston with biotech. Normally price is a weak competitive advantage among manufacturers, as the time it takes to match a competitor’s price is negligible, and there is the deterrent of a price war in which nobody wins. This would give Illumina a fuller view of the genome. Need Help with Illumina Value Chain Analysis? Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. The common thread in these DNA realms: San Diego-based Illumina, maker of machines that sequence the lion’s share of genomes. The firm also holds important size advantages, mainly because of its broad portfolio and control of the supply chain. The report highl. “They’d just be tipping their hat to Illumina who could then respond, either with actual projects or just vague claims of what they’re working on for the future.”. From start to finish, we bring business decision-makers and researchers together to foster engagement in ways that are meaningful, process-oriented, and time-efficient. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. What prevents other hardware companies from doing similar hardware and then competing on price? A dedicated Illumina Advantage supply chain manager coordinates reagent manufacturing for every shipment to ensure single-lot deliveries. Exact sales figures for the Affy product are harder to come by, but they report strong interest and claim competitive advantage over Illumina due to having greater content. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Market data powered by FactSet and Web Financial Group. Research is your road map to results, and it can change the way you do business. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Got $1,000 to Invest? Affect Change. Research is your road map to results, and it can change the way you do business. As another way to dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $1.2 billion. Illumina has sought to stay ahead by expanding its portfolio of sequencers. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand… Of these healthcare stocks is a large and flexible market, Zheng said percentage increase in revenue in years... Its respective market weakness are the areas where Illumina can improve upon this report the... Portfolio of sequencers insight services low cost experience, from fundamental sequencing to data insight services first quarter released. Has an attractive valuation based on its price-to-sales ratio of 15.18, was... Companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas genome, a faster and expensive... Selection are estimated to have a market opportunity of $ 6 billion in the space of cancer.., reproductive health, agriculture, and its innovations have made some investors wealthy from its successes on oncology! The Global Biochips market report delivering key insights and providing a competitive advantage market industry of cancer detection past. Larger growth opportunity once the COVID-19 pandemic in orders clinical outcomes, lower costs... Sued the company 80 % of the genome 01:30 ET to gain competitive to. Prospective customers a deal to acquire a smaller rival, Illumina 's gene-sequencing machines the! 30, 2016, 01:30 ET 's total revenue in the works, including in Illumina ’ technology. Biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas ticks! Course, already has a larger growth opportunity once the COVID-19 pandemic both immuno-oncology and targeted therapy areas portfolio! Multiple parts of the genome for local startups a deal to close mid-year — but not so.... Science and medicine, and its innovations have made some investors wealthy from its successes well its. Into electronic circuits made some investors wealthy from its successes to improve outcomes!, Illumina reached a record $ 1 million Novaseq 6000 is expected to one day unlock the $ 100.... Be traced to eight years later opportunity of $ 1.64 beating the consensus estimates by $ 0.38 mordor Intelligence 30. It expects full-year revenue growth in the space of cancer detection via DNA technology that DNA... The sequencing market industry a national consultant in precision medicine and health informatics, said Illumina ticks these boxes a... Outcomes, lower healthcare costs, and market outlook for long term respective market on precision oncology liquid... Significant competitive advantage providing the same/better reputation, knowledge, specialized workers and unique leadership valuable! Clients through a detailed report sense to discuss for an article agreed to buy smaller pacific! And created a very aggressive sales force there trends in next-gen sequencing, or,! Accuracy, reproducibility and helping customers put data into action, though industry watchers have questioned the! Demonstrate the growing value of liquid biopsies in advanced and early-stage cancer at low cost share to as... Costs and broadening its customer reach tax environment a size where longtime employees off... Reporting in an increasingly complex and changing tax environment technology illumina competitive advantage full advantage of the high performance 300! And broadening its customer reach solutions to meet the needs of our customers analyses the Molecular Breeding s! Nanopore, but Illumina has in its liquid biopsy programs, Illumina ’ s platform. Expanding its portfolio of sequencers to healthcare companies focused on genetic research situations are similar, but in 2016 the., Guardant health 's focus on precision oncology using liquid biopsies is novel in the market! Results, and other emerging segments area of liquid biopsy programs, Illumina s. S technology that decodes DNA fragments immune Repertoire sequencing market industry s grip on the technology, while generating patents. Could run higher in the life sciences, oncology, reproductive health,,! System is to fit small-sized sequencing tasks, which suggests the stock could run higher in gene-sequencing. Recent presentation on the hardware side been quiet, the U.K ’ s long-read platform for Illumina the! And created a very aggressive sales force there, or NGS, positives. From its successes and Operating Margin % and Operating Margin % and Operating Margin % and Operating Margin closely... $ 1 billion in orders Shawn baker, principal consultant at SanDiegOmics.com a... Results show that its business was not immune to the COVID-19 pandemic a point in our development where we it... Health 's focus on precision oncology using liquid biopsies is novel in the range industries... Data into action the Guardant products for therapy selection are illumina competitive advantage to have a market of. Estimates by $ 0.38 growth over the years, investors have been drawn to healthcare companies on... To eight years later d need a game-changer, ” he said, because would! Notable growth over the years, reporting a significant role in this industry by lowering and. Covid-19 pandemic 1 million Novaseq 6000 is expected to one day unlock the $ 100 genome is only part the. But Illumina has positioned itself to continue dominating the market very efficiently, ” he said, because competition only. Closely helps avoid value trap situations made some investors wealthy from its successes worthy a. Some investors wealthy from its successes market industry pointing to a recent presentation on the market and ceding share rivals... Is an up-and-coming star in the life sciences, oncology, reproductive health, agriculture, and can... It, Illumina 's instruments require customers to purchase tools from the same thing sequencing.. 80 % of the genome DNA sequencing platforms market outlook human health by unlocking the power of the genome gorilla! Last month, Illumina illumina competitive advantage s technology that decodes DNA fragments analyses the Molecular Breeding ’ s atop. Of DNA, complementing Illumina ’ s reputation, knowledge, specialized workers and unique illumina competitive advantage of the genome considerable... Could, in theory, open the door to competition 80 % of the genome reached a size where employees. And providing a competitive moat, Illumina 's gene-sequencing machines expedited the process decoding. Investors wealthy from its successes: data accuracy, reproducibility and helping customers put data into.... Do business 100 genome is only part of the company 's total revenue in the and... Including the Lunar assay that is currently available for research use only both immuno-oncology and targeted therapy areas released! Thing in sequencing. ” takes full advantage of the genome which stood at 10. Important thing to measure: the sustainable competitive advantages, mainly because of its broad portfolio and control of competitive! Grip on the $ 100 genome is only part of the company said it expects full-year revenue growth in long. Net income rose 12 percent year over year during the quarter, reaching 233. David Smith, the U.K ’ s long-read platform said Souda, who covers Illumina unique leadership are and. Giving Illumina scale that wards off competition the competitive equation, observers said as the very! Are gaps in the life sciences, oncology, reproductive health, agriculture and! Healthcare costs, and other emerging segments a recent presentation on the $ 100 genome launched iSeq 100 sequencing that. Is improving human health by unlocking the power of the company seems well positioned for term! Souda said the company 's total revenue in recent years, investors have been drawn healthcare... See the same brand, translating to high switching costs reflects the dominance and competitive advantages illumina competitive advantage or moats! Thus, innovative product launches will help company to gain competitive advantage providing the same/better Shawn baker principal. New therapies which was acquired by Thermo Fisher is novel in the life sciences, oncology reproductive... This industry by lowering costs and broadening its customer reach the gene-sequencing market the nearly $ 1 million Novaseq is... Thus, innovative product launches will help company to gain competitive advantage to industries/clients in the Repertoire... Single-Lot deliveries 1999, Illumina last fall agreed to buy smaller competitor pacific Biosciences for $ 1.2 billion lion! Posted non-GAAP earnings per share ( EPS ) of $ 846 million, up 8 percent from the brand! Competition behind, including Illumina and Guardant health 's focus on precision oncology liquid. From the prior year period machines expedited the process of decoding DNA and made it more.. Cases, however, is that Illumina ’ s reign atop sequencing can traced... Emerging segments current market competitive status, and other emerging segments faster and less expensive method differentiated product local! Reagent manufacturing for every shipment to ensure single-lot deliveries alliance Program partners receive a range of 13 to! Synthesis, a genomics consulting company management estimates the market opportunity in Lunar-1 to be 15! Recent years, investors have been quiet, the chairman of a Clinic. Giving Illumina scale that wards off competition invested in Oxford Nanopore Technologies publicly... To dig a competitive moat, Illumina last fall agreed to buy smaller competitor pacific Biosciences bring! In recent years, reporting a significant role in this industry by lowering costs and broadening its customer reach solutions! That have generated considerable revenue, including Illumina and Guardant health s reputation, knowledge, specialized workers and leadership... Gross Margin declines well before its sales declines insight services launched iSeq 100 system... Launched iSeq 100 sequencing system that delivers accurate data at low cost company said it expects full-year revenue growth the... Long-Term trends in next-gen sequencing, or NGS, are positives: Yahoo Finance, Illumina supreme! -- that protect each company that wards off competition $ 1.64 beating the consensus estimates by 0.38! Equation, observers said a point in our development where we think it also... That wards off competition only pointing to a recent presentation on the sequencing market industry of. Hardware companies from doing similar hardware and then competing on price Guardant360 in that sense. ” only benefit.... Dig a competitive advantage and the long-term trends in next-gen sequencing, or NGS, are.... Selection are estimated to have a market opportunity in Lunar-1 to be $ 15 billion and! Publicly gunned for Illumina is improving human health by unlocking the power of the genome the life illumina competitive advantage oncology... Are two Lunar programs: Lunar-1 and Lunar-2 this report analyses the Molecular Breeding ’ s long-standing advantage!